share_log

BRIEF-Living Cell Technologies Secures Funding For Third Clinical Trial Of NTCELL In Parkinson's Disease

BRIEF-Living Cell Technologies Secures Funding For Third Clinical Trial Of NTCELL In Parkinson's Disease

Brief-Living Cell Technologies为NTCELL治疗帕金森病的第三次临床试验获得资金
reuters ·  2021/10/18 20:56

Oct 19 (Reuters) - Living Cell Technologies Ltd LCT.AX :

路透10月19日电-Living Cell Technologies Ltd LCT.AX:

* SECURED FUNDING FOR A THIRD CLINICAL TRIAL OF NTCELL IN PARKINSON'S DISEASE

*获得资金,用于NTCELL在帕金森病中的第三次临床试验

* COMPLETED PLACEMENT RAISING A$3.5 MILLION

*完成配售,筹集350万澳元

Source text for Eikon: ID:nASXbgXbmM Further company coverage: LCT.AX

Eikon的源文本:ID:nASXbgXbmM进一步的公司报道:LCT.AX

((Reuters.Briefs@thomsonreuters.com;))

(Reurs.Briefs@thomsonreurs.com;)

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发